Several days ago, the EHC received a statement from Novo Nordisk concerning manufacturing issues related to NovoSeven, NovoEight, and Esperoct.

“The previous issue of potentially underfilled vials in certain batches of NovoSeven® 1mg and 2mg, NovoEight®, and Esperoct® has been resolved. Consequently, the supply situation for NovoSeven® is expected to gradually stabilize throughout 2025, followed by stock rebuilding. Additionally, Novo Nordisk is collaborating with local health authorities and the EMA to implement temporary mitigation measures aimed at ensuring supply flexibility across the EU and minimizing disruptions at the patient level. Overall, ongoing efforts are being made to guarantee stable production and dependable supply for patients.”

Novo Nordisk added that it is important to note that the situation in real time may differ country to country and recommends local patient organisations to work closely with the local Novo Nordisk affiliate directly to address any supply concerns.

The EHC will keep monitoring the situation and would be grateful to be informed by its members should any of you face specific problems or have concerns.